source
- BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readoutsBristol Myers Squibb, long recognized for its oncology work, is re‑investing in neurological and psychiatric disease programs, a move rooted in assets gained from its 2019 $74 billion Celgene merge…
- CAR T therapy moves from cancer to autoimmune disease, leveraging oncology safety lessonsCell therapy that transformed treatment of blood cancers is now being tested for autoimmune disorders, according to a recent opinion piece. Early cancer trials showed high complete response rates…